Role of Multiplex PCR in CAP

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06097117
Collaborator
(none)
66
13

Study Details

Study Description

Brief Summary

  1. role of multiplex PCR in early identifying bacteria in patients with lower respiratory tract infection.

  2. effect of early starting targeted antibiotics on outcome

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: MultiplexPCR

Detailed Description

Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality. Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical management of pneumonia patients and is a big challenge for conventional microbiological methods. The development and implementation of molecular diagnostic tests for pneumonia has been a major advance in the microbiological diagnosis of respiratory pathogens in recent years. Targeted antibiotic selection and more effective de-escalation and improved stewardship for pneumonia patients.

PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.

Each PCR assay requires the presence of template DNA, primers, nucleotides, and DNA polymerase .The DNA polymerase is the key enzyme that links individual nucleotides together to form the PCR product. The nucleotides include the four bases - adenine, thymine, cytosine, and guanine (A, T, C, G) - that are found in DNA. These act as the building blocks that are used by the DNA polymerase to create the resultant PCR product. The primers in the reaction specify the exact DNA product to be amplified. The primers are short DNA fragments with a defined sequence complementary to the target DNA that is to be detected and amplified. These serve as an extension point for the DNA polymerase to build on.There are multiple advantages to PCR. First, it is a simple technique to understand and to use, a nd it produces results rapidly. It is a highly sensitive technique with the potential to produce millions to billions of copies of a specific product for sequencing, cloning, and analysis. Although PCR is a valuable technique, it does have limitations. Because PCR is a highly sensitive technique, any form of contamination of the sample by even trace amounts of DNA can produce misleading results . In addition, in order to design primers for PCR, some prior sequence data is needed. Therefore, PCR can only be used to identify the presence or absence of a known pathogen or gene

Study Design

Study Type:
Observational
Anticipated Enrollment :
66 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Molecular Methods for Identifying Bacteria in Lower Respiratory Tract Specimens Among Patients With Pneumonia by Multiplex PCR
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
one group undergoes multiplex PCR

treatment will be started according targeted antibiotics

Diagnostic Test: MultiplexPCR
PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.

the other group undergoes simple culture and sensitivity

empirical antibiotics will be started until results appear and according results ,treatment will be completed or shifted to another treatment or be narrowed ,later on detect outcome of both groups.

Outcome Measures

Primary Outcome Measures

  1. detect Antimicrobial therapy duration in CAP in comparison in both groups [1 year]

    Antimicrobial therapy duration in patients with CAP in comparison of two groups

  2. detect clinical improvement in both groups [1 year]

    detection of clinical improvement in both groups (subsided of bronchial symptoms as productive cough ,colored sputum, relieve of dysnea and pleuritic chest pain , subsided of fever

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • male and female

  • Age >18 years Old

Adult patients were included if they fulfilled:
  • radiographic and clinical criteria.

  • Radiographic findings included chest imaging with an airspace opacity, lobar consolida-tion, or interstitial opacities

  • new or worsening compared to available baseline. In addition, at least 2 of the following clinical criteria had to be fulfilled:

  1. reported or documented fever > 37.5

  2. new worsening productive cough or increase in respiratory secretions in intubated patients

  3. pleuritic chest pain 4) new/worsening dyspnea or hypoxia, defined as documented blood oxygen saturation <92%.

Exclusion Criteria:

Patients under 18 years old. Patients who refuse to participate in the study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Asmaa Saleh Mousa Ali, Resident doctor at Chest department, Assiut University
ClinicalTrials.gov Identifier:
NCT06097117
Other Study ID Numbers:
  • role of multiplex PCR in CAP
First Posted:
Oct 24, 2023
Last Update Posted:
Oct 24, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 24, 2023